Pavella Therapeutics initiates coverage with outperform rating; target price $228
PVLA•Leerink Partners initiated coverage of Pavella Therapeutics with an outperform rating and a $228 target price.
PVLA•Leerink Partners initiated coverage of Pavella Therapeutics with an outperform rating and a $228 target price.
